Essa Pharma - EPIX STOCK NEWS

ESSA Pharma Inc. (NASDAQ: EPIX) provides a corporate update and financial results for Q3 ended June 30, 2022. The company reported a net loss of $8.8 million ($0.20 loss per share), consistent with the previous year. R&D expenditures increased slightly to $6.4 million. ESSA's lead candidate, EPI-7386, advanced to the dose expansion phase of its clinical trial, showing safety and initial anti-tumor activity. Cash reserves stand at $174.6 million, sufficient to fund operations through 2024.

ESSA Pharma Inc. (EPIX) presented promising Phase 1a trial results for EPI-7386, a novel prostate cancer treatment, indicating the drug was well-tolerated and achieved significant efficacy in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). Out of 36 participants, the drug showed initial anti-tumor effects with reduced tumor volumes and stable PSA levels. The company plans to initiate a Phase 1b expansion study in Q3 2022. Notably, EPI-7386 may be explored in combination with other therapies to enhance its efficacy against prostate cancer.

ESSA Pharma Inc. (NASDAQ: EPIX), a clinical-stage pharmaceutical company dedicated to prostate cancer therapies, is set to present at the 2022 Jefferies Healthcare Conference in New York City on June 9, 2022, at 3:00 p.m. ET. David R. Parkinson, the President and CEO, along with CFO David S. Wood, will participate in one-on-one meetings during the event. The presentation will follow a fireside chat format and will be accessible via a webcast on the company's website. The archived webcast will be available for 90 days.

ESSA Pharma Inc. (NASDAQ: EPIX) announced its fiscal second-quarter results for the period ending March 31, 2022, reporting a net loss of $10.9 million or $0.25 per share, an improvement from a $13.0 million loss a year ago. The company continues dosing patients in a Phase 1a trial of EPI-7386, a novel androgen receptor inhibitor for metastatic castration-resistant prostate cancer (mCRPC). ESSA's cash reserves stand at $181.0 million, sufficient to fund operations through 2024. Clinical updates on EPI-7386 are anticipated in 2022.

ESSA Pharma Inc. (NASDAQ: EPIX) announced its participation in the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022, at 2:30 p.m. ET. The company's President and CEO, David R. Parkinson, will host one-on-one meetings along with COO Peter Virsik and CFO David S. Wood. The event will be held at the Metro Toronto Convention Centre, offering investors insights into the latest developments in the healthcare sector. A webcast of the presentation will be available on ESSA's website and archived for 90 days.

ESSA Pharma Inc. (NASDAQ: EPIX) has announced the presentation of preclinical data on its ANITAC™ degraders at the 2022 American Association for Cancer Research Annual Meeting. ANITAC degraders target the N-terminal domain of androgen receptors, showing potential to degrade both full length and mutant forms in castration-resistant prostate cancer (CRPC). The data indicates these degraders can inhibit AR-dependent transcription and effectively reduce the viability of AR-dependent prostate cancer cells. Further developments are anticipated this year.

ESSA Pharma Inc. (NASDAQ: EPIX) will present at the virtual Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 2:40 p.m. ET. David R. Parkinson, President and CEO, alongside COO Peter Virsik and CFO David S. Wood, will engage in one-on-one meetings during the event. ESSA focuses on developing innovative therapies for prostate cancer. A webcast of the presentation will be available on the company's website and archived for 90 days following the event.

ESSA Pharma Inc. (NASDAQ: EPIX) announced the results of its Annual General Meeting of Shareholders held virtually on March 9, 2022. Shareholders set the board of directors at eight members, re-electing all members, including David R. Parkinson and Richard M. Glickman, with high approval percentages. The shareholders also approved the re-appointment of Davidson & Company LLP as auditors and amended the omnibus incentive plan to increase share reserves. Additionally, they supported a non-binding advisory vote on executive compensation frequency for one year.

ESSA Pharma Inc. (EPIX) presented preclinical data on its androgen receptor (AR) N-terminal domain degraders, ANITAC™, at the AACR Annual Meeting 2022. The degraders effectively suppressed AR transcriptional activity and reduced prostate cancer cell viability in castration-resistant prostate cancer (CRPC) models. The data highlighted the ability of ANITAC™ to degrade various forms of AR expressed in CRPC patients. This innovative approach targets a significant challenge in treating advanced prostate cancer, where patients often develop resistance to existing therapies.